title: Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: cost, safety, and long-term efficacy.
abstract: BACKGROUND
  Few data are available on the cost, safety, and long-term efficacy of single-agent high-dose melphalan (HDM) followed by autologous bone marrow (ABMT) or blood stem cell (ABSCT) transplantation in the salvage therapy of Hodgkin's disease (HD).
  
  
  METHODS
  From February 1981 to September 1996, 23 patients with relapsed (n = 15) or refractory (n = 8) HD received salvage therapy with HDM 140-200 mg/m2 followed by non-cryopreserved ABMT (n = 18) or cryopreserved ABSCT (n = 5). The cost of HDM/ABSCT in 1996, from initial consultation until transfer back to referring physician, was determined and compared to the estimate costs of two multi-agent regimens commonly used for HD.
  
  
  RESULTS
  HDM was well tolerated with no early transplant-related mortality. The five-year overall and progression-free survival rates were 52% and 50%, respectively. The average total cost in Canadian funds of HDM/ABSCT in 1996 was $34,400/patient. This cost was estimated to be $4,700-6,800 cheaper per patient than the multi-agent high-dose regimens.
  
  
  CONCLUSIONS
  These data suggest that HDM is safe, feasible, active, and reasonably inexpensive salvage therapy for patients with relapsed/refractory HD.
authors.affiliation: Department of Medical Oncology, Tom Baker Cancer Centre, Foothills Hospital, Calgary, Alberta, Canada.
authors.forename: D A
authors.initials: DA
authors.lastname: Stewart
authors.forename: D
authors.initials: D
authors.lastname: Guo
authors.forename: J A
authors.initials: JA
authors.lastname: Sutherland
authors.forename: B A
authors.initials: BA
authors.lastname: Ruether
authors.forename: A R
authors.initials: AR
authors.lastname: Jones
authors.forename: M C
authors.initials: MC
authors.lastname: Poon
authors.forename: C
authors.initials: C
authors.lastname: deMetz
authors.forename: J
authors.initials: J
authors.lastname: Klassen
authors.forename: A
authors.initials: A
authors.lastname: Chaudhry
authors.forename: C B
authors.initials: CB
authors.lastname: Brown
authors.forename: J A
authors.initials: JA
authors.lastname: Russell
mesh_terms: D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D008875:Middle Aged
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan